EKF Diagnostics

Joe Keenan Appointed Head of Life Sciences at LetsGetChecked

Retrieved on: 
Wednesday, November 8, 2023

LetsGetChecked, a global healthcare solutions company, announced today that it has appointed Joe Keenan to Head of Life Sciences on its Commercial Team.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company, announced today that it has appointed Joe Keenan to Head of Life Sciences on its Commercial Team.
  • “His extensive experience will be instrumental as we continue to scale our life sciences platform and broader diagnostic strategy at LetsGetChecked.
  • I have no doubt Joe will deliver impactful results within the life sciences market and help drive better outcomes for patients."
  • "I am pleased to join LetsGetChecked and am eager to build on the company’s success to date,” said Joe Keenan, Head of Life Sciences at LetsGetChecked.

Urinalysis Market is Expected to Reach $5.7 billion | MarketsandMarkets

Retrieved on: 
Tuesday, February 7, 2023

The consumables segment accounted for the largest share of the urinalysis market, by product segment, in 2021

Key Points: 
  • The consumables segment accounted for the largest share of the urinalysis market, by product segment, in 2021
    Based on product, the urinalysis market is segmented into consumables and instruments.
  • The pregnancy & fertility tests segment accounted for the largest share of the urinalysis market, by test type segment, in 2021
    Based on test type, the urinalysis market is segmented into pregnancy & fertility tests, biochemical tests and sediment urinalysis.
  • The diseases screening segment accounted for the largest share of the urinalysis market, by application segment, in 2021
    Based on application, the urinalysis market is segmented into disease screening and pregnancy & fertility tests.
  • North America accounted for the largest regional market for urinalysis market in 2021.

Urinalysis Market is Expected to Reach $5.7 billion | MarketsandMarkets

Retrieved on: 
Tuesday, February 7, 2023

The consumables segment accounted for the largest share of the urinalysis market, by product segment, in 2021

Key Points: 
  • The consumables segment accounted for the largest share of the urinalysis market, by product segment, in 2021
    Based on product, the urinalysis market is segmented into consumables and instruments.
  • The pregnancy & fertility tests segment accounted for the largest share of the urinalysis market, by test type segment, in 2021
    Based on test type, the urinalysis market is segmented into pregnancy & fertility tests, biochemical tests and sediment urinalysis.
  • The diseases screening segment accounted for the largest share of the urinalysis market, by application segment, in 2021
    Based on application, the urinalysis market is segmented into disease screening and pregnancy & fertility tests.
  • North America accounted for the largest regional market for urinalysis market in 2021.

Directorate Change

Retrieved on: 
Sunday, November 27, 2022

OTAQ, the innovative technology company targeting the aquaculture, geotracking and offshore markets, announces the appointment of Adam Reynolds as Non-Executive Chairman with immediate effect.

Key Points: 
  • OTAQ, the innovative technology company targeting the aquaculture, geotracking and offshore markets, announces the appointment of Adam Reynolds as Non-Executive Chairman with immediate effect.
  • The Company also announces that Alex Hambro will retire as Non-Executive Chairman of the Company at the same time.
  • He brings with him a wealth of knowledge and experience across various sectors and helps companies realise their potential.
  • The following information relating to Adam Reynolds is disclosed pursuant to Rule 4.9 of the AQSE Growth Market - Access Rulebook.

POC Hba1C Testing Global Market to Reach $2.43 Billion By 2026 at a CAGR of 8.9%

Retrieved on: 
Monday, October 17, 2022

DUBLIN, Oct. 17, 2022 /PRNewswire/ --The "Poc Hba1C Testing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 17, 2022 /PRNewswire/ --The "Poc Hba1C Testing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the POC HbA1C testing market in 2021.
  • The regions covered in POC HbA1C testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
  • The increasing prevalence of diabetes is expected to propel the growth of the POC HbA1C testing market.

POC Hba1C Testing Global Market Report 2022: Skyrocketing Diabetes Rates Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022

The "POC Hba1C Testing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "POC Hba1C Testing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in POC HbA1C testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
  • The increasing prevalence of diabetes is expected to propel the growth of the POC HbA1C testing market.
  • Therefore, the increasing prevalence of diabetes is driving the growth of the POC HbA1C testing market.

Pharus, Inc. Names Philip C. Huang as Company CEO, Becomes Newest Player in Cancer Liquid Biopsy Market

Retrieved on: 
Monday, October 3, 2022

LOS ANGELES, Oct. 3, 2022 /PRNewswire/ -- Pharus, Inc. ("PharusDx"), a new diagnostics company spun out from Hsinchu, Taiwan-based Quark Biosciences, has named Philip Huang as its Chief Executive Officer. PharusDx creates solutions for the early detection of cancer and is currently developing its OncoSweep™ Multi-Cancer Early Detection (MCED) liquid biopsy test as well as single-cancer liquid biopsy tests that evaluate microRNA (miRNA) within the body.

Key Points: 
  • PharusDx creates solutions for the early detection of cancer and is currently developing its OncoSweepMulti-Cancer Early Detection (MCED) liquid biopsy test as well as single-cancer liquid biopsy tests that evaluate microRNA (miRNA) within the body.
  • Before joining Roche, Mr. Huang was Vice President of Global Business Development for EKF Diagnostics, a UK point-of-care diagnostics company, where he led corporate strategy and solidified strategic partnerships.
  • PharusDx is entering the precision medicine market with the goal of changing cancer diagnosis, so that medical professionals can detect and treat cancer early, before it progresses to advanced disease.
  • Using OncoSweepMCED and single-cancer liquid biopsy tests, physicians can find circulating biomarkers for multiple forms of cancer by testing blood or other body fluid samples.

Global Clinical Chemistry Analyzers Market to Reach $15.7 Billion by 2026

Retrieved on: 
Tuesday, November 16, 2021

SAN FRANCISCO, Nov. 16, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Clinical Chemistry Analyzers - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Nov. 16, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Clinical Chemistry Analyzers - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Clinical Chemistry Analyzers estimated at US$12.1 Billion in the year 2020, is projected to reach a revised size of US$15.7 Billion by 2026, growing at a CAGR of 4.5% over the analysis period.
  • This segment currently accounts for a 25% share of the global Clinical Chemistry Analyzers market.
  • The U.S. Market is Estimated at $4.4 Billion in 2021, While China is Forecast to Reach $1.6 Billion by 2026
    The Clinical Chemistry Analyzers market in the U.S. is estimated at US$4.4 Billion in the year 2021.

Diagnostic Enzyme Global Markets Analysis & Forecasts, 2015-2019, 2023F, 2025F, 2030F - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 19, 2021

Major players in the diagnostic enzymes market are Genzyme, Roche, Codexis, Aldevron, Kaneka Eurogentec, Vigene Biosciences, Amano Enzymes, Advanced Enzymes Technologies, Thermo Fisher Scientific and EKF Diagnostic.

Key Points: 
  • Major players in the diagnostic enzymes market are Genzyme, Roche, Codexis, Aldevron, Kaneka Eurogentec, Vigene Biosciences, Amano Enzymes, Advanced Enzymes Technologies, Thermo Fisher Scientific and EKF Diagnostic.
  • The diagnostic enzymes market consists of the sales of diagnostic enzymes and related services by entities (organizations, sole traders, and partnerships) that manufacture diagnostic enzymes.
  • The changes in temperature and pH levels may decrease the efficiency of the diagnostic enzymes that, in turn, hampers the growth of the diagnostic enzymes market.
  • Global Diagnostic Enzymes Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

Companion Diagnostics Market Research Report 2021 - Global Growth, Trends, Covid-19 Impact, and Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021

The "Companion Diagnostics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Companion Diagnostics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the global companion diagnostics market can be attributed to the rising focus on personalized medicine and the co-development of drug and diagnostic technologies.
  • Overall, the rising R&D activities in the development of novel diagnostic test for various chronic diseases is anticipated to drive the global companion diagnostics market growth.
  • The Companion Diagnostics Market is moderately fragmented and highly competitive consists of several major players.